MUC16 and lung cancer: A dose-dependent decrease in the proliferation of a panel of MUC16 expressing pancreatic (SW1990, inhibition 35%, P = 0.00057; COLO357, inhibition 45%, P = 0.01587) and lung cancer (SW1573, inhibition 40%, P = 0.0208; H2122, inhibition 35%, P = 0.0471) cell lines were observed upon treatment with ch5E6 than isotype control huIgG1 while non-MUC16 expressing lines MIA PaCa-2 and A549 did not show such effects (Fig. 2e, Supplementary Fig. 2, a).